Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Nutrients ; 15(4)2023 Feb 04.
Article in English | MEDLINE | ID: mdl-36839167

ABSTRACT

Heart rate variability (HRV) provides a simple method to evaluate autonomic function in health and disease. A reduction in HRV may indicate autonomic dysfunction and is strongly associated with aspects of cardiometabolic disease, including hyperglycemia. Reduced nitric oxide (NO) bioavailability is also implicated in the development of cardiometabolic disease and autonomic dysfunction. Watermelons are natural sources of L-arginine and L-citrulline, substrates used for NO synthesis. Watermelon consumption can improve NO bioavailability. We conducted a randomized, double-blind, placebo-controlled crossover trial to test the effects of 2 weeks of daily watermelon juice (WMJ) supplementation on HRV in response to an oral glucose challenge (OGC) in healthy young adults. We also performed indirect calorimetry to assess if our intervention altered the metabolic response to the OGC. WMJ supplementation preserved high-frequency power (HF) (treatment effect, p = 0.03) and the percentage of successive differences that differ by more than 50 ms (pNN50) (treatment effect, p = 0.009) when compared to the placebo treatment. There was no difference in resting energy expenditure or substate oxidation according to treatment. We report that WMJ supplementation attenuates OGC-induced reductions in HRV. Future work should emphasize the importance of NO bioavailability in autonomic dysfunction in cardiometabolic disease.


Subject(s)
Cardiovascular Diseases , Citrullus , Young Adult , Humans , Heart Rate , Dietary Supplements , Citrullus/chemistry , Cross-Over Studies , Glucose/pharmacology , Double-Blind Method
2.
Cancer Res ; 79(9): 2327-2338, 2019 05 01.
Article in English | MEDLINE | ID: mdl-31043430

ABSTRACT

When pancreatic cancer cannot be removed surgically, patients frequently experience morbidity and death from progression of their primary tumor. Radiation therapy (RT) cannot yet substitute for an operation because radiation causes fatal bleeding and ulceration of the nearby stomach and intestines before achieving tumor control. There are no FDA-approved medications that prevent or reduce radiation-induced gastrointestinal injury. Here, we overcome this fundamental problem of anatomy and biology with the use of the oral EGLN inhibitor FG-4592, which selectively protects the intestinal tract from radiation toxicity without protecting tumors. A total of 70 KPC mice with autochthonous pancreatic tumors received oral FG-4592 or vehicle control ± ablative RT to a cumulative 75 Gy administered in 15 daily fractions to a limited tumor field. Although ablative RT reduced complications from local tumor progression, fatal gastrointestinal bleeding was observed in 56% of mice that received high-dose RT with vehicle control. However, radiation-induced bleeding was completely ameliorated in mice that received high-dose RT with FG-4592 (0% bleeding, P < 0.0001 compared with vehicle). Furthermore, FG-4592 reduced epithelial apoptosis by half (P = 0.002) and increased intestinal microvessel density by 80% compared with vehicle controls. EGLN inhibition did not stimulate cancer growth, as treatment with FG-4592 alone, or overexpression of HIF2 within KPC tumors independently improved survival. Thus, we provide a proof of concept for the selective protection of the intestinal tract by the EGLN inhibition to enable ablative doses of cytotoxic therapy in unresectable pancreatic cancer by reducing untoward morbidity and death from radiation-induced gastrointestinal bleeding. SIGNIFICANCE: Selective protection of the intestinal tract by EGLN inhibition enables potentially definitive doses of radiation therapy. This might allow radiation to be a surgical surrogate for unresectable pancreatic cancer.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/9/2327/F1.large.jpg.


Subject(s)
Glycine/analogs & derivatives , Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors , Isoquinolines/pharmacology , Pancreatic Neoplasms/mortality , Radiation Injuries/prevention & control , Radiation-Protective Agents/pharmacology , Radiotherapy/mortality , Animals , Apoptosis , Female , Glycine/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/radiotherapy , Proto-Oncogene Proteins p21(ras)/physiology , Radiation Injuries/etiology , Radiation Injuries/mortality , Radiotherapy/adverse effects , Transcription Factors/physiology , Tumor Suppressor Protein p53/physiology
4.
J Clin Invest ; 115(3): 718-27, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15711641

ABSTRACT

Hepatic insulin resistance is a critical component in the development of type 2 diabetes mellitus. In many cases, insulin resistance in liver is associated with reduced expression of both major insulin receptor substrate (IRS) proteins, IRS-1 and IRS-2. To investigate the specific functions of IRS-1 and IRS-2 in regulating liver function in vivo, we developed an adenovirus-mediated RNA interference technique in which short hairpin RNAs (shRNAs) are used to knock down IRS-1, IRS-2, or both, by 70-80% in livers of WT mice. The knockdown of IRS-1 resulted in an upregulation of the gluconeogenic enzymes glucose-6 phosphatase and phosphoenolpyruvate carboxykinase, as well as a marked increase in hepatic nuclear factor-4 alpha. Decreased IRS-1 was also associated with a decrease in glucokinase expression and a trend toward increased blood glucose, whereas knockdown of IRS-2 resulted in the upregulation of lipogenic enzymes SREBP-1c and fatty acid synthase, as well as increased hepatic lipid accumulation. The concomitant injection of IRS-1 and IRS-2 adenoviral shRNAs resulted in systemic insulin resistance, glucose intolerance, and hepatic steatosis. The alterations in the dual-knockdown mice were associated with defective Akt activation and Foxo1 phosphorylation. Taken together, our results demonstrate that hepatic IRS-1 and IRS-2 have complementary roles in the control of hepatic metabolism, with IRS-1 more closely linked to glucose homeostasis and IRS-2 more closely linked to lipid metabolism.


Subject(s)
Liver/metabolism , Phosphoproteins/metabolism , RNA Interference , Adenoviridae/genetics , Adenoviridae/metabolism , Adipocytes/metabolism , Animals , Enzyme Activation , Fatty Acids/metabolism , Gene Expression Regulation , Gluconeogenesis/genetics , Gluconeogenesis/physiology , Glucose/metabolism , Homeostasis , Insulin/metabolism , Insulin Receptor Substrate Proteins , Intracellular Signaling Peptides and Proteins , Leptin/metabolism , Liver/cytology , Liver/pathology , Liver/physiology , Male , Mice , Mice, Inbred C57BL , Phosphatidylinositol 3-Kinases/metabolism , Phosphoproteins/genetics , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , RNA, Small Interfering/chemistry , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism
5.
Atherosclerosis ; 145(2): 425-32, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10488974

ABSTRACT

OBJECTIVE: The Carotene and Retinol Efficacy Lung Cancer Chemoprevention Trial (CARET) ended prematurely due to the unexpected findings that the active treatment group on the combination of 30 mg beta-carotene and 25,000 IU retinyl palmitate had a 46% increased lung cancer mortality and a 26% increased cardiovascular mortality compared with placebo. This study was designed when the CARET intervention was halted to evaluate the effects of long-term supplementation with beta-carotene and retinol on serum triglyceride and cholesterol levels, in an attempt to explore possible explanations for the CARET result. METHODS: Serum triglyceride levels, and total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol levels were determined in a subgroup of 52 CARET participants. Baseline and mid-trial levels were available on 23 participants on placebo and 29 on active treatment who were then serially followed for 10 months after trial termination. RESULTS: Triglyceride, and total, HDL and LDL cholesterol levels were similar in the two groups at baseline. After a mean of 5 years on the intervention there was a small nonsignificant increase in serum triglyceride levels in the active group, but no difference in total, HDL, or LDL cholesterol levels. After stopping the intervention there was a decrease in triglyceride levels in the active intervention group, and no change in the other parameters. CONCLUSION: Based on a small convenience sample, CARET participants in the active treatment arm had a small nonsignificant increase in serum triglyceride levels while on the intervention, and a decrease in serum triglyceride levels after the intervention was discontinued. No significant changes in total or HDL cholesterol were noted. These results argue against a major contribution of treatment-induced changes in serum lipid and lipoprotein levels to the increased cardiovascular mortality in the active treatment group.


Subject(s)
Cholesterol/blood , Lung Neoplasms/prevention & control , Triglycerides/blood , Vitamin A/therapeutic use , beta Carotene/therapeutic use , Cardiovascular Diseases/blood , Cardiovascular Diseases/mortality , Cardiovascular Diseases/prevention & control , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Chromatography, High Pressure Liquid , Female , Follow-Up Studies , Humans , Lung Neoplasms/blood , Lung Neoplasms/mortality , Male , Middle Aged , Survival Rate , Treatment Outcome , Vitamin A/pharmacokinetics , beta Carotene/pharmacokinetics
6.
Atherosclerosis ; 143(2): 427-34, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10217373

ABSTRACT

OBJECTIVE: The Carotene and Retinol Efficacy Lung Cancer Chemoprevention Trial (CARET) ended prematurely due to the unexpected findings that the active treatment group on the combination of 30 mg beta-carotene and 25,000 IU retinyl palmitate had a 46% increased lung cancer mortality and a 26% increased cardiovascular mortality compared with placebo. This study was designed when the CARET intervention was halted to evaluate the effects of long-term supplementation with beta-carotene and retinol on serum triglyceride and cholesterol levels, in an attempt to explore possible explanations for the CARET result. METHODS: Serum triglyceride levels, and total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol levels were determined in a subgroup of 52 CARET participants. Baseline and mid-trial levels were available on 23 participants on placebo and 29 on active treatment who were then serially followed for 10 months after trial termination. RESULTS: Triglyceride, and total, HDL and LDL cholesterol levels were similar in the two groups at baseline. After a mean of 5 years on the intervention there was a small nonsignificant increase in serum triglyceride levels in the active group, but no difference in total, HDL, or LDL cholesterol levels. After stopping the intervention there was a decrease in triglyceride levels in the active intervention group, and no change in the other parameters. CONCLUSION: Based on a small convenience sample, CARET participants in the active treatment arm had a small nonsignificant increase in serum triglyceride levels while on the intervention, and a decrease in serum triglyceride levels after the intervention was discontinued. No significant changes in total or HDL cholesterol were noted. These results argue against a major contribution of treatment-induced changes in serum lipid and lipoprotein levels to the increased cardiovascular mortality in the active treatment group.


Subject(s)
Antioxidants/administration & dosage , Cholesterol/blood , Lipoproteins, HDL/blood , Triglycerides/blood , Vitamin A/administration & dosage , beta Carotene/administration & dosage , Adult , Arteriosclerosis/prevention & control , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Lipoproteins, HDL/drug effects , Male , Middle Aged , Reference Values , Sampling Studies , Time Factors
7.
Clin Oncol (R Coll Radiol) ; 10(3): 170-2, 1998.
Article in English | MEDLINE | ID: mdl-9704179

ABSTRACT

The effect of brief neoadjuvant chemotherapy in patients with apparently operable adenocarcinoma of the oesophagus has been investigated. Two courses of cisplatin and 5-fluorouracil (CFu) were given, followed by evaluation of the response by barium swallow. Twenty-one of 23 patients completed both courses. Two showed a complete response and five a partial response. In only one patient was there a pathological complete response. Toxicity was mild and consisted principally of nausea and vomiting. All patients underwent surgical exploration; resection was completed in 17. There were three hospital deaths (18%). Although CFu has produced two complete responses (on barium swallow) and one complete pathological clearance of tumour, the disappointing total response rate of 7/21 (33%; 95% CI 13-53) or 7/23 (30%; 95% CI 12-49) leads us to believe that further Phase II trials are needed to identify more efficacious agents and regimens.


Subject(s)
Adenocarcinoma/drug therapy , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/administration & dosage , Esophageal Neoplasms/drug therapy , Fluorouracil/administration & dosage , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/surgery , Aged , Antimetabolites, Antineoplastic/adverse effects , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Barium Sulfate , Cause of Death , Chemotherapy, Adjuvant , Cisplatin/adverse effects , Contrast Media , Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/surgery , Evaluation Studies as Topic , Female , Fluorouracil/adverse effects , Humans , Male , Middle Aged , Nausea/chemically induced , Radiography , Remission Induction , Survival Rate , Vomiting/chemically induced
8.
Cancer Epidemiol Biomarkers Prev ; 7(3): 211-4, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9521435

ABSTRACT

The Carotene and Retinol Efficacy Trial (CARET), a randomized, placebo-controlled lung cancer chemoprevention trial of 30 mg of beta-carotene and 25,000 IU of retinyl palmitate, was prematurely terminated when a 46% excess lung cancer mortality was found in subjects on the active arm. Before the CARET intervention ended, 21 men were recruited to participate in a 6-month biomarker study using the same intervention as CARET that determined the effect of this supplementation on lung nutrient levels. Plasma and bronchoalveolar lavage (BAL) cell nutrient levels were measured before and after the intervention. The group in the active arm (n = 10) had plasma carotene level increases of over 10-fold, with a small increase in plasma retinol levels BAL cell levels of beta-carotene in the active group also increased 10-fold, from 4.5 to 46.3 pmol/10(6) cells (P = 0.0008), with no change in BAL cell retinol levels. Surgically obtained lung tissue from three CARET subjects in the active arm showed elevated carotene lung tissue levels but no increase in lung retinol levels compared to a group of surgical controls. Combined with our previous work showing a strong correlation between BAL and lung tissue nutrient levels, these findings suggest that supplementation with beta-carotene and vitamin A results in increased lung tissue as well as BAL cell levels of beta-carotene, with little change in lung retinol.


Subject(s)
Anticarcinogenic Agents/pharmacology , Carotenoids/blood , Lung Neoplasms/pathology , Lung/drug effects , Vitamin A/analogs & derivatives , beta Carotene/pharmacology , Aged , Anticarcinogenic Agents/pharmacokinetics , Asbestosis/pathology , Bronchoalveolar Lavage Fluid/chemistry , Bronchoscopy , Diterpenes , Double-Blind Method , Humans , Lung/pathology , Male , Middle Aged , Retinyl Esters , Risk Factors , Smoking/adverse effects , Smoking/pathology , Vitamin A/pharmacokinetics , Vitamin A/pharmacology , beta Carotene/pharmacokinetics
9.
Clin Oncol (R Coll Radiol) ; 10(6): 372-6, 1998.
Article in English | MEDLINE | ID: mdl-9890538

ABSTRACT

The effect of neoadjuvant chemotherapy in patients with apparently operable adenocarcinoma of the oesophagus has been investigated. Two courses of mitomycin, cisplatin and 5-fluorouracil (MCF) were given, followed by a radiological evaluation of response. Twenty-two of 25 patients completed both courses. Two showed a complete response and 12 a partial response. There was a pathological complete response of the primary tumour in only one patient (although there was residual secondary tumour in a local lymph node). The main toxicity was myelosuppression, with 9/22 patients having the second chemotherapy course delayed. There were three sudden deaths, one due to a pulmonary embolus and two due to complications of infections. Twenty-one patients underwent surgical exploration; there were 18 resections. Although the radiological response rate of MCF (14/25; 56%; 95% CI 37-75) appeared promising, there were no pathological complete responders. Further Phase II trials are needed to identify more efficacious agents and regimens that will yield a pathological response rate of at least 10%, before proceeding to randomized trials of neoadjuvant chemotherapy for adenocarcinoma of the oesophagus.


Subject(s)
Adenocarcinoma/surgery , Antibiotics, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/administration & dosage , Esophageal Neoplasms/surgery , Fluorouracil/administration & dosage , Mitomycins/administration & dosage , Adenocarcinoma/drug therapy , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/adverse effects , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cause of Death , Chemotherapy, Adjuvant , Cisplatin/adverse effects , Esophageal Neoplasms/drug therapy , Esophagectomy/methods , Female , Fluorouracil/adverse effects , Humans , Leukopenia/chemically induced , Male , Middle Aged , Mitomycins/adverse effects , Neoadjuvant Therapy , Neoplasm Staging , Preoperative Care , Remission Induction , Survival Rate
10.
Am J Respir Crit Care Med ; 155(3): 1066-71, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9116988

ABSTRACT

The association between serum beta-carotene or retinol concentration and level of ventilatory function was investigated in a population of asbestos-exposed men with a high rate of current and former cigarette smoking. The study population consisted of 816 subjects enrolled in the pilot component of the Carotene and Retinol Efficacy Trial (CARET), a placebo-controlled trial of supplemental beta-carotene and retinyl palmitate for the chemoprevention of lung cancer. Data available for analysis included baseline questionnaire, spirometry, chest X-ray, food frequency questionnaire, and serum beta-carotene and retinol concentrations. Serum beta-carotene concentration was associated with FEV1 (p < 0.05) and FVC (p < 0.05), with an approximately 100-ml increase over predicted values associated with raising the serum concentration from the 25th to the 75th percentile of the distribution in the study population (absolute difference = 155 ng/ml), even after adjustment for the confounding effects of asbestos exposure and cigarette smoking. Raising the serum retinol concentration from the 25th to the 75th percentile (absolute difference = 211 ng/ml) was associated with an approximately 70 ml increase in FVC (p < 0.05) over the predicted value. These results provide support for the hypothesis that beta-carotene and retinol have a protective effect on loss of ventilatory function.


Subject(s)
Asbestos , Occupational Exposure , Respiration/physiology , Vitamin A/blood , beta Carotene/blood , Aged , Clinical Trials as Topic , Cross-Sectional Studies , Forced Expiratory Volume , Humans , Male , Middle Aged , Pilot Projects , Risk Assessment , Smoking/physiopathology , Time Factors , Vital Capacity
11.
N Engl J Med ; 334(18): 1150-5, 1996 May 02.
Article in English | MEDLINE | ID: mdl-8602180

ABSTRACT

BACKGROUND: Lung cancer and cardiovascular disease are major causes of death in the United States. It has been proposed that carotenoids and retinoids are agents that may prevent these disorders. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled primary prevention trial -- the Beta Carotene and Retinol Efficacy Trial -- involving a total of 18,314 smokers, former smokers, and workers exposed to asbestos. The effects of a combination of 30 mg of beta carotene per day and 25,000 IU of retinol (vitamin A) in the form of retinyl palmitate per day on the primary end point, the incidence of lung cancer, were compared with those of placebo. RESULTS: A total of 388 new cases of lung cancer were diagnosed during the 73,135 person-years of follow-up (mean length of follow-up, 4.0 years). The active-treatment group had a relative risk of lung cancer of 1.28 (95 percent confidence interval, 1.04 to 1.57; P=0.02), as compared with the placebo group. There were no statistically significant differences in the risks of other types of cancer. In the active-treatment group, the relative risk of death from any cause was 1.17 (95 percent confidence interval, 1.03 to 1.33); of death from lung cancer, 1.46 (95 percent confidence interval, 1.07 to 2.00); and of death from cardiovascular disease, 1.26 (95 percent confidence interval, 0.99 to 1.61). On the basis of these findings, the randomized trial was stopped 21 months earlier than planned; follow-up will continue for another 5 years. CONCLUSIONS: After an average of four years of supplementation, the combination of beta carotene and vitamin A had no benefit and may have had an adverse effect on the incidence of lung cancer and on the risk of death from lung cancer, cardiovascular disease, and any cause in smokers and workers exposed to asbestos.


Subject(s)
Antioxidants/therapeutic use , Cardiovascular Diseases/prevention & control , Carotenoids/therapeutic use , Lung Neoplasms/prevention & control , Vitamin A/therapeutic use , Aged , Antioxidants/adverse effects , Asbestos/adverse effects , Cardiovascular Diseases/mortality , Carotenoids/adverse effects , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Incidence , Lung Neoplasms/chemically induced , Lung Neoplasms/epidemiology , Male , Middle Aged , Mortality , Occupational Exposure , Risk , Smoking/adverse effects , Vitamin A/adverse effects , beta Carotene
12.
Nature ; 380(6571): 243-7, 1996 Mar 21.
Article in English | MEDLINE | ID: mdl-8637571

ABSTRACT

The hypothalamus plays a central role in the integrated regulation of energy homeostasis and body weight, and a number of hypothalamic neuropeptides, such as neuropeptide Y (ref. 1), galanin, CRH (ref. 3) and GLP-1 (ref. 4), have been implicated in the mediation of these effects. To discover new hypothalmic peptides involved in the regulation of body weight, we used differential display polymerase chain reaction to identify messenger RNAs that are differentially expressed in the hypothalamus of ob/+ compared with ob/ob C57B1/6J mice. We show here that one mRNA that is overexpressed in the hypothalamus of ob/ob mice encodes the neuropeptide melanin-concentrating hormone (MCH). Fasting further increased expression of MCH mRNA in both normal and obese animals. Neurons containing MCH are located in the zona incerta and in the lateral hypothalamus. These areas are involved in regulation of ingestive behaviour, but the role of MCH in mammalian physiology is unknown. To determine whether MCH is involved in the regulation of feeding, we injected MCH into the lateral ventricles of rats and found that their food consumption increased. These findings suggest that MCH participates in the hypothalamic regulation of body weight.


Subject(s)
Feeding Behavior/physiology , Hypothalamic Hormones/physiology , Hypothalamus/physiology , Melanins/physiology , Pituitary Hormones/physiology , Amino Acid Sequence , Animals , Base Sequence , Blotting, Northern , DNA , Fasting , Hypothalamic Hormones/administration & dosage , Hypothalamic Hormones/genetics , Injections, Intraventricular , Male , Melanins/administration & dosage , Melanins/genetics , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Obesity/metabolism , Pituitary Hormones/administration & dosage , Pituitary Hormones/genetics , Polymerase Chain Reaction , RNA, Messenger/analysis
13.
Exp Neurol ; 131(2): 229-38, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7534721

ABSTRACT

There is evidence that central infusion of brain-derived neurotrophic factor (BDNF) induces weight loss in rats. We have begun to investigate the physiological basis for BDNF-induced weight loss by assessing its relationship to (a) appetite, (b) serum indices of metabolic and renal toxicity, and (c) brain monoamine activity in areas associated with feeding or motor function. BDNF (0-6 microgram/day) was infused into the lateral ventricle (LV) of male Long-Evans rats for 14 days. Body weight and food intake were monitored throughout infusion and recovery periods. BDNF induced severe, dose-dependent appetite suppression and weight loss. Although appetite began to recover after the 10th infusion day, body weight had not returned to control values at the end of the recovery period. The weight loss observed in BDNF-infused rats was related to appetite suppression, since uninfused rats that were pair-fed to high dose BDNF-treated rats showed comparable weight loss. Despite severe weight loss, serum BUN, creatinine, thyroxine, glucose, and total protein were not affected by BDNF infusion. Striatal DO-PAC/DA was similarly unaffected by BDNF. In contrast, BDNF-infused rats showed a dose-dependent increase in hypothalamic 5-HIAA/5-HT that was not observed in pair-fed rats, suggesting that the observed increase in hypothalamic 5-HIAA/5-HT was a direct effect of BDNF infusion rather than a secondary effect of food restriction. These data suggest that BDNF may induce appetite suppression and weight loss through a central mechanism.


Subject(s)
Anorexia/chemically induced , Appetite Depressants/toxicity , Corpus Striatum/metabolism , Hypothalamus/metabolism , Nerve Tissue Proteins/toxicity , Serotonin/metabolism , Weight Loss/drug effects , 3,4-Dihydroxyphenylacetic Acid/metabolism , Animals , Anorexia/blood , Anorexia/physiopathology , Appetite Depressants/administration & dosage , Brain-Derived Neurotrophic Factor , Corpus Striatum/pathology , Dopamine/metabolism , Dose-Response Relationship, Drug , Feeding Behavior/drug effects , Feeding Behavior/physiology , Hydroxyindoleacetic Acid/metabolism , Hypothalamus/pathology , Infusion Pumps, Implantable , Injections, Intraventricular , Insulin/blood , Kidney Function Tests , Male , Nerve Tissue Proteins/administration & dosage , Rats , Thyroxine/blood
14.
Cancer Res ; 54(7 Suppl): 2038s-2043s, 1994 Apr 01.
Article in English | MEDLINE | ID: mdl-8137335

ABSTRACT

CARET is a multicenter, two-armed, double-masked randomized chemoprevention trial in Seattle, Portland, San Francisco, Baltimore, Connecticut, and Irvine, to test whether oral administration of beta-carotene (30 mg/day) plus retinyl palmitate (25,000 IU/day) can decrease the incidence of lung cancer in high risk populations, namely, heavy smokers and asbestos-exposed workers. The intervention combines the antioxidant action of beta-carotene and the tumor suppressor mechanism of vitamin A. As of April 30, 1993, CARET had randomized 1,845 participants in the 1985-1988 pilot phase plus 13,260 "efficacy" participants since 1989; of these, 4,000 are asbestos-exposed males and 11,105 are smokers and former smokers (44% female). Accrual is complete everywhere except Irvine, which was the last center added (1991), and the safety profile of the regimen to date has been excellent. With 14,420 smokers, 4,010 asbestos-exposed participants, and 114,100 person-years through February 1998, we expect CARET to be capable of detecting a 23% reduction in lung cancer incidence in the two populations combined and 27, 49, 32, and 35% reductions in the smokers, female smokers, male smokers, and asbestos-exposed subgroups, respectively. CARET is highly complementary to the alpha-tocopherol-beta-carotene study in Finland and the Harvard Physicians Health Study (beta-carotene alone) in the National Cancer Institute portfolio of major cancer chemoprevention trials.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Asbestos/adverse effects , Carotenoids/therapeutic use , Lung Neoplasms/prevention & control , Occupational Exposure , Smoking/adverse effects , Vitamin A/analogs & derivatives , Aged , Carotenoids/adverse effects , Diterpenes , Female , Follow-Up Studies , Humans , Lung Neoplasms/epidemiology , Lung Neoplasms/etiology , Male , Middle Aged , Pilot Projects , Retinyl Esters , Risk Factors , United States , Vitamin A/adverse effects , Vitamin A/therapeutic use , beta Carotene
15.
Article in English | MEDLINE | ID: mdl-8130548

ABSTRACT

This paper describes a prototype information sources map (ISM), an on-line information source finder, for Occupational and Environmental Medicine (OEM). The OEM ISM was built as part of the Unified Medical Language System (UMLS) project of the National Library of Medicine. It allows a user to identify sources of on-line information appropriate to a specific OEM question, and connect to the sources. In the OEM ISM we explore a domain-specific method of indexing information source contents, and also a domain-specific user interface. The indexing represents a domain expert's opinion of the specificity of an information source in helping to answer specific types of domain questions. For each information source, an index field represents whether a source might provide useful information in an occupational, industrial, or environmental category. Additional fields represent the degree of specificity of a source in individual question types in each category. The paper discusses the development, design, and implementation of the prototype OEM ISM.


Subject(s)
Abstracting and Indexing , Environmental Health , Occupational Medicine , Online Systems , User-Computer Interface , Computer Communication Networks , Computer Graphics , Information Services , Software , Unified Medical Language System
18.
J Occup Med ; 32(11): 1104-7, 1990 Nov.
Article in English | MEDLINE | ID: mdl-2258766

ABSTRACT

Demand is increasing rapidly for medical evaluation and management of individuals and groups exposed to chemical, physical, and biologic hazards in the non-workplace environment. Because general physicians are ill prepared to respond and no existing specialty has obvious expertise, occupational physicians who have some relevant background could have a central role to play in filling these perceived needs. However, incorporation of environmental medicine into the specialty will require reexamination of our skills and training. The focus of this essay is to explore aspects of environmental medicine practice that demand expansion of the current repertoire of skills. Based on these, we propose modifications of training that could facilitate such expansion without sacrifice of the core principles of traditional occupational medicine.


Subject(s)
Curriculum , Environmental Health , Occupational Medicine/education , Research , United States
19.
Eur J Surg Oncol ; 15(4): 341-4, 1989 Aug.
Article in English | MEDLINE | ID: mdl-2547664

ABSTRACT

Eight patients with local Stage II (T2N1) and III (T3N0, T3N1, T2N2) small cell lung cancer received combination chemotherapy prior to elective surgery to assess the effectiveness of such a regimen in improving operability, preventing local relapse and extending survival. The regimen was well tolerated and prevented local relapse. However, the median time to recurrence of disease was 10 months and the median survival time 13 months, results which are similar to those achieved with chemotherapy and radiotherapy. Distant metastases, particularly in the brain, occurred predictably indicating that successful adjuvant surgery, despite preventing local relapse, may not afford additional survival benefit with currently available drug regimens.


Subject(s)
Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/surgery , Lung Neoplasms/drug therapy , Lung Neoplasms/surgery , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Small Cell/mortality , Carcinoma, Small Cell/pathology , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Leucovorin/administration & dosage , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lymphatic Metastasis , Male , Methotrexate/administration & dosage , Middle Aged , Neoplasm Staging , Pneumonectomy , Preoperative Care , Remission Induction , Vincristine/administration & dosage
20.
Arch Intern Med ; 148(11): 2401-4, 1988 Nov.
Article in English | MEDLINE | ID: mdl-3190373

ABSTRACT

Using a mailed survey questionnaire directed toward division chiefs of general internal medicine, we have confirmed that despite increased interest among faculty, few medical residents currently receive required or elective training in occupational medicine. However, recent changes in societal perceptions about environmental risks, corporate health care practices, and medical reimbursement patterns favoring provision by hospitals of contractual outpatient services to healthy workers all portend expanded involvement of residents in certain occupational medicine activities in the future, in response to economic pressures on both consumers and providers. These same forces may, unfortunately, undermine the scientific and ethical quality of such training experiences, compared with emerging, more academically motivated approaches. The implications of these prospects are analyzed in the hope that a proper balance can ultimately be struck between economic and academic imperatives.


Subject(s)
Environmental Health , Internal Medicine/education , Internship and Residency , Occupational Medicine , Humans , Surveys and Questionnaires , Teaching/methods
SELECTION OF CITATIONS
SEARCH DETAIL